MetaSight develops a proprietary metabolomics, lipidomics, and proteomics platform that enables accurate and affordable diagnostics through a single blood test. This technology provides early diagnostic biomarkers for various diseases, including cancer and metabolic disorders, facilitating non-invasive population-scale screening.
Funding
$8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current diagnostic techniques, such as genomic-based liquid biopsies, are often unsuitable for conditions outside of oncology and can be expensive for population-wide screening. There is a need for non-invasive tests that can accurately diagnose, monitor, and provide prognosis for a wide range of diseases.
Solution
MetaSight offers a metabolomics, lipidomics, and proteomics platform designed to provide accurate and affordable diagnostics through a single blood test. This technology aims to identify early diagnostic biomarkers for various diseases, including cancer and metabolic disorders, making non-invasive population-scale screening feasible. MetaSight leverages a large clinico multi-OMICS database, generated using their proprietary unbiased platform, to optimize patient care through improved disease diagnosis, monitoring, and prognosis.
Target Audience
The primary target audience includes healthcare providers, diagnostic laboratories, and research institutions seeking accurate, affordable, and accessible diagnostic tools for diverse diseases.
Features
- Proprietary metabolomics, lipidomics, and proteomics platform for comprehensive analysis.
- Development of early diagnostic biomarkers for various diseases.
- Application of technology to cancer and metabolic disorders.
- Facilitation of non-invasive population-scale screening.
- Clinico multi-OMICS database for improved accuracy and insights.